Reflecting on 2023 at AVI
James Biggins, CEO & President
As 2023 draws to a close, I find myself pausing to reflect on the journey we've taken at Access Vascular over the past year, a stage marked by both significant challenges and extraordinary achievements. It's a journey that speaks not just to our team at AVI, but to the wider medical community, as we all navigate the complexities of our industry.
Resilience in the Face of Adversity: This year, the resilience and adaptability of our team have been a beacon of hope and a demonstration of perseverance. Amidst ongoing global challenges, our team has proven an unwavering commitment to excellence and innovation. The mantra of “we’ll figure it out” has been our guide, steering us through challenging circumstances with determination and the spirit of teamwork.
Series C Funding - A Testament to Confidence and Growth: A pivotal moment of 2023 was our successful Series C financing round, where we raised an impressive $22 million. This significant achievement is a proof point for the confidence our investors have in AVI's vision and the potential of our
advanced biomaterial technology. This funding is earmarked for scaling up the production of our innovative MIMIX™ hydrophilic biomaterial vascular access devices, a crucial step in meeting the growing demand for fewer complications and thus more effective medical solutions.
Innovations in Biomaterial Technology: Our advancements in biomaterial technology have been nothing short of groundbreaking. The results from our studies presented at the AVA Annual Scientific Meeting have shown our MIMIX hydrophilic biomaterial (HBM) to significantly reduce bacterial adhesion and thrombus accumulation.(1) This innovation could revolutionize the way we approach vascular access, with the potential to significantly lower the risks associated with central-line associated bloodstream infections (CLABSI). It's a shining example of how AVI is leading the way in medical device innovation.
HydroPICC® Study - Paving the Way for Future Success: The publication of our peer-reviewed study of the HydroPICC® peripherally inserted central catheter in the Journal of Materials Science: Materials in Medicine is another milestone we're incredibly proud of and adds to the previously published HydroMID® data demonstrating 6X fewer complications. This study reinforces the safety and efficacy of our cutting-edge catheter technology, underlining our commitment to transforming vascular access.
As we look ahead to 2024, I am filled with immense pride and gratitude for our AVI team and our broader family of stakeholders. Your hard work, dedication, and innovative spirit have been the driving force behind our success. It is your relentless pursuit of excellence that will continue to drive us forward, as we strive to transform vascular access and impact the lives of patients and medical professionals alike.
As the CEO of Access Vascular, my promise for 2024 is to remain dedicated and accessible, supporting our team in every endeavor as we continue to break new ground in medicine. Here's to a future where our shared vision, teamwork, and culture continue to guide us through any storm, always keeping in mind that at the heart of all we do are the people we serve – the hospitals, the clinicians, and the patients.
Wishing everyone a prosperous and innovative 2024.
James Biggins, CEO of Access Vascular
